Articles | Volume 7, issue 4
https://doi.org/10.5194/jbji-7-169-2022
© Author(s) 2022. This work is distributed under the Creative Commons Attribution 4.0 License.
Original full-length article
| 
27 Jul 2022
Original full-length article |
| 27 Jul 2022
| 27 Jul 2022
Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistant Staphylococcus aureus implant-associated osteomyelitis
Related authors
J. Bone Joint Infect., 8, 143–149, 2023
Cited articles
Alder, K. D., Lee, I., Munger, A. M., Kwon, H.-K., Morris, M. T., Cahill,
S. V., Back, J., Kristin, E. Y., and Lee, F. Y.: Intracellular
Staphylococcus aureus in bone and joint infections: A mechanism of disease recurrence,
inflammation, and bone and cartilage destruction, Bone, 141, 115568, https://doi.org/10.1016/j.bone.2020.115568, 2020.
Asempa, T. E., Abdelraouf, K., Carabeo, T., Schuch, R., and Nicolau, D. P.:
Synergistic activity of exebacase (CF-301) in addition to daptomycin against
Staphylococcus aureus in a neutropenic murine thigh infection model, Antimicrob. Agents
Chemother., 64, e02176–02119, 2019.
Chambers, H. F., Basuino, L., Diep, B., Steenbergen, J., Zhang, S.,
Tattevin, P., and Alder, J.: Relationship between susceptibility to
daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis,
Antimicrob. Agents Chemother., 53, 1463–1467, 2009.
Clinicaltrials.gov: Direct lysis of Staph aureus resistant pathogen trial of exebacase (DISRUPT),
NCT04160468, http://clinicaltrials.gov, last access: 24 September 2021.
Cobb, L. H., Park, J., Swanson, E. A., Beard, M. C., McCabe, E. M., Rourke,
A. S., Seo, K. S., Olivier, A. K., and Priddy, L. B.: CRISPR-Cas9 modified
bacteriophage for treatment of Staphylococcus aureus induced osteomyelitis and soft tissue
infection, PLoS One, 14, e0220421, https://doi.org/10.1371/journal.pone.0220421, 2019.
